Insulin Glargine 300units/ml (high strength preparation)

Green-G

Brand Name(s):Toujeo

Indication:Diabetes Type 1& 2

Rationale:

Considered:Dec-15

Review Date:May-22

Comments:
Updated NG 17- diagnosis and management diagnosis and management
July 2016
…………………………
NICE NG28 Update Type 2 diabetes in adults: management
May 2017
…………………………
Prescribe as brand.
Toujeo is a high strength insulin glargine preparation – 300units/ml. Caution should be taken when prescribing to ensure the patient is aware of the strength.
Toujeo is NOT bioequivalent to Insulin Lantus
For information on bioequivalence and prescribing safely please refer to:

https://www.gov.uk/drug-safety-update/high-strength-fixed-combination-and-biosimilar-insulin-products-minimising-the-risk-of-medication-error
Jan 2016

NICE guidelines [NG18]
Diabetes (type 1 and type 2) in children and young people: diagnosis and management
Full document available at:http://www.nice.org.uk/guidance/ng18
Aug 2015
…………………………
NICE NG17
Type 1 diabetes in adults: diagnosis and management
Full details available at:http://www.nice.org.uk/guidance/ng17/resources/type-1-diabetes-in-adults-diagnosis-and-management-1837276469701
Aug 2015
…………………………
NICE has recommended insulin glargine as an option for people with type 1 diabetes. For people with type 2 diabetes who need to take insulin, NICE has recommended that insulin glargine should be an option only if the person:

needs help with his or her insulin injections from a carer or healthcare professional, or
has repeated and unpleasant hypoglycaemic episodes that significantly affect his or her way of life, or
would otherwise need to have two insulin injections to maintain background levels every day as well as having to take other diabetes medicines orally.

The recommendations in this technology appraisal relating to type 2 diabetes have been replaced by recommendations in the Diabetes – type 2 (update) clinical guideline published in May 2008. Please note that the recommendations in this technology appraisal relating to type 1 diabetes have not changed.

NICE Guidance TA53

Also see NYRDTC Guidance using the following link:
http://www.nyrdtc.nhs.uk/docs/dud/DU_66_Insulin_Analogues.pdf?zoom_highlight=Diabetes#search=”Diabetes”